小细胞肺癌作为第二原发肿瘤的临床特征

目的探讨小细胞肺癌作为第二原发肿瘤的临床特征。方法回顾分析美国康州Hartford医院Helen＆Harry Gray癌症中心10年诊治的355例小细胞肺癌，其中经正规治疗者165例。作为第二原发肿瘤发生于其他恶性肿瘤之后的小细胞肺癌48例，经正规治疗者28例。结果48例小细胞肺癌诊断之前患有其他恶性肿瘤，占13．5％，其中包括头颈部癌4例（8．3％），皮肤癌11例（22．9％，其中2例为三原发肿瘤），非小细胞肺癌2例（4．2％），乳腺癌6例（12．5％），胃肠肿瘤5例（10．4％），妇科肿瘤3例（6．3％），男性泌尿生殖道肿瘤5例（10．4％），前列腺癌13例（27．1％），血液系统肿瘤2例（4．2％）。三原发肿瘤5例（10．4％）。有吸烟史者93％（40／43例）。发生在前列腺癌后的患者与发生在皮肤癌后的患者相比，年龄较大，正规治疗者较少，生存期较短（分别为3．5月和15月）。在28例正规治疗患者中，11例完全缓解（39．3％），12例部分缓解（42．9％），其生存期为5．1～77．7月（中位11．3月）；20例未治疗患者的生存期为0．5～34．0月（中位2．0月）。165例经正规治疗过的第一原发SCLC的中位生存期（13．5月）、缓解率（77．6％）与28例第二原发SCLC（11．3月，82．1％）均无显著差异。（P〉0．05）。结论小细胞肺癌作为第二原发肿瘤的发生率为13．5％，其中三原发肿瘤为10．4％。其治疗有效率和生存期与一般小细胞肺癌均无差异。发生在前列腺癌后的患者可能比发生在皮肤癌后的患者预后差。

Clinical Course Of Patients with Small Cell Lung Cancer As Second Primary Malignancy

Objective: To evaluate the clinical course of patients with small cell lung cancer (SCLC) as second primary malignancy. Methods: Among the 355 patients diagnosed with SCLC at Helen and Harry Gray Cancer Center of Hartford Hospital Connecticut USA between 1988 and 1998, the records of 48 patients, which had been diagnosed with other malignancies before their diagnosis of SCLC, were retrospectively reviewed. Results: Forty-eight patients (13.5%) were diagnosed with other malignancies prior to their SCLC among which 43 had documented smoking history and 93% of them (40/43) were current/ former smokers. Of the 28-second primary SCLC patients who were treated with standard method, 11 (39.3%) achieved CR, 12 (42.8%) achieved PR, and the RR was 82.1%. The median survival of the 28 treated with standard method was 11.3 months (5.1-77.7 months), while that of the rest 19 untreated patients (1 of 20 was lost to follow-up) was only 2.0 months (0.5-34.0 months). There was no significant difference in the median survival and RR between 165 treated first primary SCLC (13.5 months and 77.6% respectively) and 28 treated secondary primary SCLC (11.3 months and 82.1% respectively) (P>0.05). The patients who had prostate cancer were older and subjected to less treatments than those with skin cancer, so their survival was shorter than the latter (3.5 months vs. 15 months, P<0.05). Conclusion: The response and survival of the treated patients with SCLC as a second malignancy showed no difference as compared to the treated ones with SCLC only. Therefore, an active medical treatment is important to relieve symptom and prolong survival of the second primary SCLC patients.